Global Information
회사소개 | 문의 | 비교리스트

세계의 광선각화증 치료제 시장(2020-2024년)

Global Actinic Keratosis Drugs Market 2020-2024

리서치사 TechNavio (Infiniti Research Ltd.)
발행일 2020년 06월 상품 코드 943515
페이지 정보 영문 120 Pages
가격
US $ 2,500 ₩ 2,947,000 PDF by E-mail (Single User License) help
1명만 이용할 수 있는 라이선스입니다. PDF 파일은 Copy & Paste가 가능합니다. 인쇄횟수에 제한은 없으나, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 3,000 ₩ 3,536,000 PDF by E-mail (5-user License) help
동일 사업장 내 5명까지 공유하여 이용할 수 있는 라이선스입니다. PDF 파일은 Copy & Paste가 가능합니다. 인쇄횟수에 제한은 없으나, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 4,000 ₩ 4,715,000 PDF by E-mail (Enterprise License) help
동일 기업 내 모든 분들이 공유하여 이용할 수 있는 라이선스입니다. 이용 인원수에 제한은 없습니다. PDF 파일은 Copy & Paste가 가능합니다. 인쇄횟수에 제한은 없으나, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 5,000 ₩ 5,894,000 PDF by E-mail (Global License) help
동일 기업 내 모든 분들이 공유하여 이용할 수 있는 라이선스입니다. 이용 인원수에 제한은 없습니다. PDF 파일은 Copy & Paste가 가능합니다. 인쇄횟수에 제한은 없으나, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다. 또한 해당 라이선스는 보고서 컨텐츠의 15% 이내로 외부용 문서에 인용 게재가 허용됩니다(예:프레스릴리스, 마케팅 자료, 백서 등).


세계의 광선각화증 치료제 시장(2020-2024년) Global Actinic Keratosis Drugs Market 2020-2024
발행일 : 2020년 06월 페이지 정보 : 영문 120 Pages

세계의 광선각화증 치료제 시장은 2020-2024년간 3%의 CAGR로 확대되어 5억 2,014만 달러로 성장할 전망입니다. 광선성 각화증의 높은 유병률은 시장 성장을 지지할 것으로 예상됩니다.

세계의 광선각화증 치료제(Actinic Keratosis Drugs) 시장을 조사했으며, 시장 개요, 시장 성장 촉진요인 및 저해요인 분석, 종류별·지역별 시장 규모 추정과 예측, 벤더 분석, 시장 기회 등의 정보를 제공합니다.

목차

주요 요약

시장 상황

시장 규모

  • 시장 정의
  • 시장 부문 분석
  • 2019년 시장 규모
  • 시장 전망 : 2019-2024년 예측

Five Forces 분석

약물 클래스별 시장 세분화

  • 시장 부문
  • 약물 클래스별 비교
  • 뉴클레오시드 대사 억제제 - 시장 규모와 예측(2019-2024년)
  • 면역조절제 - 시장 규모와 예측(2019-2024년)
  • 광증감제 - 시장 규모와 예측(2019-2024년)
  • NSAIDs - 시장 규모와 예측(2019-2024년)
  • 약물 클래스별 시장 기회

고객 상황

지역별 상황

  • 지역별 세분화
  • 지역별 비교
  • 북미 - 시장 규모와 예측(2019-2024년)
  • 아시아태평양 - 시장 규모와 예측(2019-2024년)
  • 유럽 - 시장 규모와 예측(2019-2024년)
  • 기타 지역 - 시장 규모와 예측(2019-2024년)
  • 주요 국가
  • 지역의 시장 기회
  • 성장 촉진요인
  • 시장 과제
  • 시장 동향

벤더 상황

  • 벤더 상황
  • 창조적 파괴 상황

벤더 분석

  • 대상 벤더
  • 벤더의 시장 포지셔닝
  • 3M Co.
  • Almirall SA
  • Bausch Health Companies Inc.
  • Biofrontera AG
  • Hill Dermaceuticals Inc.
  • LEO Pharma AS
  • Mylan NV
  • Nestle SA
  • Novartis AG
  • Sun Pharmaceutical Industries Ltd.

부록

KSM 20.07.09

Technavio has been monitoring the actinic keratosis drugs market and it is poised to grow by $ 520.14 mn during 2020-2024 progressing at a CAGR of 3% during the forecast period. Our reports on actinic keratosis drugs market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.

The report offers an up-to-date analysis regarding the current global market scenario, latest trends and drivers, and the overall market environment. The market is driven by the high prevalence of actinic keratosis and availability of combination therapy. In addition, high prevalence of actinic keratosis is anticipated to boost the growth of the market as well.

The actinic keratosis drugs market analysis includes product segment and geographical landscapes

Technavio's ‘ actinic keratosis drugs market ’ is segmented as below:

By Product:

  • Nucleoside metabolic inhibitors
  • Immunomodulators
  • Photosensitizers
  • NSAIDs

By Geography: landscapes

  • North America
  • APAC
  • Europe
  • ROW

This study identifies the threat of conversion to fatal disease as one of the prime reasons driving the actinic keratosis drugs market growth during the next few years.

Technavio presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters. Our actinic keratosis drugs market covers the following areas:

  • Actinic keratosis drugs market sizing
  • Actinic keratosis drugs market forecast
  • Actinic keratosis drugs market industry analysis"

Technavio's robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading actinic keratosis drugs market vendors that include 3M Co., Almirall SA, Bausch Health Companies Inc., Biofrontera AG, Hill Dermaceuticals Inc., LEO Pharma AS, Mylan NV, Nestle SA, Novartis AG, and Sun Pharmaceutical Industries Ltd.. Also, the actinic keratosis drugs market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage on all forthcoming growth opportunities.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.

Technavio presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive research - both primary and secondary. Technavio's market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast an accurate market growth.

Table of Contents

Executive Summary

  • Market Overview

Market Landscape

  • Market ecosystem
  • Value chain analysis

Market Sizing

  • Market definition
  • Market segment analysis
  • Market size 2019
  • Market outlook: Forecast for 2019 - 2024

Five Forces Analysis

  • Five forces summary
  • Bargaining power of buyers
  • Bargaining power of suppliers
  • Threat of new entrants
  • Threat of substitutes
  • Threat of rivalry
  • Market condition

Market Segmentation by Drug class

  • Market segments
  • Comparison by Drug class
  • Nucleoside metabolic inhibitors - Market size and forecast 2019-2024
  • Immunomodulators - Market size and forecast 2019-2024
  • Photosensitizers - Market size and forecast 2019-2024
  • NSAIDs - Market size and forecast 2019-2024
  • Market opportunity by Drug class

Customer Landscape

Geographic Landscape

  • Geographic segmentation
  • Geographic comparison
  • North America - Market size and forecast 2019-2024
  • APAC - Market size and forecast 2019-2024
  • Europe - Market size and forecast 2019-2024
  • ROW - Market size and forecast 2019-2024
  • Key leading countries
  • Market opportunity by geography
  • Volume drivers - demand led growth
  • Market challenges
  • Market trends

Vendor Landscape

  • Vendor landscape
  • Landscape disruption

Vendor Analysis

  • Vendors covered
  • Market positioning of vendors
  • 3M Co.
  • Almirall SA
  • Bausch Health Companies Inc.
  • Biofrontera AG
  • Hill Dermaceuticals Inc.
  • LEO Pharma AS
  • Mylan NV
  • Nestle SA
  • Novartis AG
  • Sun Pharmaceutical Industries Ltd.

Appendix

  • Scope of the report
  • Currency conversion rates for US$
  • Research methodology
  • List of abbreviations

Exhibit

  • 1: Key Finding 1
  • 2: Key Finding 2
  • 3: Key Finding 3
  • 4: Key Finding 5
  • 5: Key Finding 6
  • 6: Key Finding 7
  • 7: Key Finding 8
  • 8: Parent market
  • 9: Market characteristics
  • 10: Offerings of vendors included in the market definition
  • 11: Market segments
  • 12: Global - Market size and forecast 2019 - 2024 ($ million)
  • 13: Global market: Year-over-year growth 2019 - 2024 (%)
  • 14: Five forces analysis 2019 & 2024
  • 15: Bargaining power of buyers
  • 16: Bargaining power of suppliers
  • 17: Threat of new entrants
  • 18: Threat of substitutes
  • 19: Threat of rivalry
  • 20: Market condition - Five forces 2019
  • 21: Other1 - Market share 2019-2024 (%)
  • 22: Comparison by Other1
  • 23: Nucleoside metabolic inhibitors - Market size and forecast 2019-2024 ($ million)
  • 24: Nucleoside metabolic inhibitors - Year-over-year growth 2019-2024 (%)
  • 25: Immunomodulators - Market size and forecast 2019-2024 ($ million)
  • 26: Immunomodulators - Year-over-year growth 2019-2024 (%)
  • 27: Photosensitizers - Market size and forecast 2019-2024 ($ million)
  • 28: Photosensitizers - Year-over-year growth 2019-2024 (%)
  • 29: NSAIDs - Market size and forecast 2019-2024 ($ million)
  • 30: NSAIDs - Year-over-year growth 2019-2024 (%)
  • 31: Market opportunity by Other1
  • 32: Customer landscape
  • 33: Market share by geography 2019-2024 (%)
  • 34: Geographic comparison
  • 35: North America - Market size and forecast 2019-2024 ($ million)
  • 36: North America - Year-over-year growth 2019-2024 (%)
  • 37: APAC - Market size and forecast 2019-2024 ($ million)
  • 38: APAC - Year-over-year growth 2019-2024 (%)
  • 39: Europe - Market size and forecast 2019-2024 ($ million)
  • 40: Europe - Year-over-year growth 2019-2024 (%)
  • 41: ROW - Market size and forecast 2019-2024 ($ million)
  • 42: ROW - Year-over-year growth 2019-2024 (%)
  • 43: Key leading countries
  • 44: Market opportunity by geography ($ million)
  • 45: Impact of drivers and challenges
  • 46: Vendor landscape
  • 47: Landscape disruption
  • 48: Industry risks
  • 49: Vendors covered
  • 50: Market positioning of vendors
  • 51: 3M Co. - Overview
  • 52: 3M Co. - Business segments
  • 53: 3M Co. - Key offerings
  • 54: 3M Co. - Key customers
  • 55: 3M Co. - Segment focus
  • 56: Almirall SA - Overview
  • 57: Almirall SA - Product and service
  • 58: Almirall SA - Key offerings
  • 59: Almirall SA - Key customers
  • 60: Almirall SA - Segment focus
  • 61: Bausch Health Companies Inc. - Overview
  • 62: Bausch Health Companies Inc. - Business segments
  • 63: Bausch Health Companies Inc. - Key offerings
  • 64: Bausch Health Companies Inc. - Key customers
  • 65: Bausch Health Companies Inc. - Segment focus
  • 66: Biofrontera AG - Overview
  • 67: Biofrontera AG - Product and service
  • 68: Biofrontera AG - Key offerings
  • 69: Biofrontera AG - Key customers
  • 70: Biofrontera AG - Segment focus
  • 71: Hill Dermaceuticals Inc. - Overview
  • 72: Hill Dermaceuticals Inc. - Product and service
  • 73: Hill Dermaceuticals Inc. - Key offerings
  • 74: Hill Dermaceuticals Inc. - Key customers
  • 75: Hill Dermaceuticals Inc. - Segment focus
  • 76: LEO Pharma AS - Overview
  • 77: LEO Pharma AS - Business segments
  • 78: LEO Pharma AS - Key offerings
  • 79: LEO Pharma AS - Key customers
  • 80: LEO Pharma AS - Segment focus
  • 81: Mylan NV - Overview
  • 82: Mylan NV - Business segments
  • 83: Mylan NV - Key offerings
  • 84: Mylan NV - Key customers
  • 85: Mylan NV - Segment focus
  • 86: Nestle SA - Overview
  • 87: Nestle SA - Business segments
  • 88: Nestle SA - Key offerings
  • 89: Nestle SA - Key customers
  • 90: Nestle SA - Segment focus
  • 91: Novartis AG - Overview
  • 92: Novartis AG - Business segments
  • 93: Novartis AG - Key offerings
  • 94: Novartis AG - Key customers
  • 95: Novartis AG - Segment focus
  • 96: Sun Pharmaceutical Industries Ltd. - Overview
  • 97: Sun Pharmaceutical Industries Ltd. - Business segments
  • 98: Sun Pharmaceutical Industries Ltd. - Key offerings
  • 99: Sun Pharmaceutical Industries Ltd. - Key customers
  • 100: Sun Pharmaceutical Industries Ltd. - Segment focus
  • 101: Currency conversion rates for US$
  • 102: Research Methodology
  • 103: Validation techniques employed for market sizing
  • 104: Information sources
  • 105: List of abbreviations
Back to Top
전화 문의
F A Q